



DIASORIN S.P.A. – THE BOARD OF DIRECTORS APPROVES THE RESULTS FOR THE THIRD QUARTER OF 2007: SHARPLY HIGHER REVENUES AND FURTHER GAINS IN PROFITABILITY

Third Quarter Financial Highlights:

- Consolidated net revenues rise to 49.0 million euros, for a gain of 12.6% (+14.7% on a comparable foreign exchange translation basis);
- EBITDA* grow to 13.5 million euros, or 15.3 million euros net of nonrecurring income/expense up from 13.5 million euros in the third quarter of 2006 (15.5 million euros as reported) for a net gain of 13.0%;
- EBIT total 10.0 million euros, or 11.9 million euros net of nonrecurring income/expense up from 10.1 million euros in the third quarter of 2006 (12.0 million euros as reported) for a net gain of 18.1%;
- Consolidated net profit totals 5.3 million euros, for a net gain of 16.8% compared to third quarter 2006 net of nonrecurring income;
- Consolidated net borrowings decrease to 15.9 million euros, compared with 30.2 million euros at June 30, 2007 and 34.7 million euros at December 31, 2006.

Saluggia, November 12, 2007 – The Board of Directors of DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics, meeting under the chairmanship of Gustavo Denegri, approved the report on operations in the third quarter of 2007 presented by Carlo Rosa, the Company's Chief Executive Officer.

In the third quarter of 2007, DiaSorin reported once again a sharp increase in revenues, even though the continuing strength of the euro versus the U.S. dollar had a dampening effect. If the

* The Company's defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of the EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

negative impact of the nonrecurring charges incurred by the Group' s Parent Company during the period is eliminated, profitability was also up appreciably.

The third quarter of 2007 ended with **revenues increasing by 12.6%** compared with the same period last year. If the data are restated net of currency exchange fluctuations, revenues show an even greater gain (+14.7%). This improvement was driven primarily by growing demand for products based on CLIA (ChemiLuminescent Immuno Assay) technology, which rose by 27%, thanks to a steady expansion of the installed base of LIAISON equipment (1,960 units compared with 1,870 units at June 30, 2007), and by an expansion of the available assay menus (14 new products, including 7 specialty products, launched between 2006 and September 2007), which produced an increase in the revenues generated by each machine. As a result, the contribution to total revenues provided by reagents based on CLIA technology increased to 51.1%.

The revenue gain produced an improvement in all profitability indicators. The **gross profit** grew by 13.5%, rising from 26.8 million euros in the third quarter of 2006 to 30.4 euros in the same period this year, with the return on sales rising from 61.5% to 62.0% over the same period.

As mentioned above, the Group' s third quarter operating results for 2006 and 2007 reflect the impact of extraordinary income and expense items. Specifically, in 2007 the Group recognized extraordinary charges totaling 1.9 million euros incurred to list the Parent Company' s shares on the online stock market in Milan. While the data for 2006 include extraordinary income of 1.9 million euros recognized in connection with the receipt of a government grant for research projects covered by Law No. 346/1998.

EBITDA totaled 13.5 million euros in the third quarter of 2007, equal to 27.5% of revenues. Consolidated **EBIT** for the third quarter of 2007 amounted to 10 million euros, equal to 20.5% of revenues. Restated to eliminate the impact of nonrecurring items, **EBITDA** show an increase of 13.1% over the third quarter of 2006, amounting to 15.3 million euros, or 31.2% of revenues. On the same basis, **EBIT** total 11.9 million euros, equal to 24.3% of revenues, for a gain of 18.1% over the third quarter of 2006.

The **net profit** totaled 5.3 million euros, equal to 10.9% of revenues, showing an increase of 16.8% over the third quarter of 2006 net of extraordinary items.

At September 30, 2007, consolidated net **borrowings** totaled 15.9 million euros, down sharply from the amounts owed at June 30, 2007 (30.2 million euros) and December 31, 2006 (34.7 million euros).

Business Development

Breakdown of Revenues by Geographic Region

A breakdown of revenues by geographic region shows solid growth rates in all of the countries in which DiaSorin has an established direct presence, with sales rising at an especially fast rate in North America.

In Europe, revenues were up 15.0% in the third quarter of 2007, increasing from 25.7 million euros to 28.7 million euros.

North America, where the development of the CLIA technology and the expansion of the installed base of Liaison equipment are relatively recent developments, continues to be one of the markets of greatest strategic importance for the Group. However, because of unfavorable changes in the euro-dollar exchange rate, the sales increase achieved in this market is not fully reflected in the percentage contribution it provided to consolidated revenues. In the third quarter of 2007, revenues totaled 11.6 million euros, or 18.0% more than in the same period last year. The gain is 27.7% if the data are restated on a comparable foreign exchange translation basis.

In markets other than Europe and North America, Group revenues grew by 9.1%. The best performance was recorded in China, where sales shot up by 30%.

(amounts in millions of euros)	Third Quarter		
	2007	2006	Change
Europe	28.7	25.7	11.6%
North America (United States and Canada)	11.6	9.9	18.0%
Rest of the world	8.7	7.9	9.1%
Total	49.0	43.5	12.6%

Breakdown of Revenues by Technology

A breakdown of revenues in terms of the technologies offered by DiaSorin shows once again that the increase was driven by a rise in sales of products based on CLIA technology, which increased by 27% in the third quarter of 2007. This rate of growth, which is higher than that of RIA or ELISA products, was made possible by an expansion of the installed base and a broadening of the portfolio of available products with the inclusion of specialty kits.

As a result, products based on CLIA technology now account for 51.1% of total revenues, up significantly from 45.3% in the third quarter of 2006.

% of revenues contributed	Third Quarter	
	2007	2006
RIA	11.5%	13.1%
ELISA	26.3%	33.4%
CLIA (Liaison)	51.1%	45.3%
Equipment and other revenues	11.1%	8.2%
Total	100.0	100.0%

Operating Performance in the First Nine Months of 2007

The DiaSorin Group performed particularly well during the first nine months of 2007. Revenues were up significantly compared with the same period last year, despite the dampening effect of the appreciation of the euro versus other currencies, particularly the U.S. dollar.

Specifically, consolidated revenues totaled 151,2 million euros in the first nine months of 2007, or 10.6% more than in the same period last year, when current exchange rates are applied. But the gain is 12.8% if the data are restated on a comparable exchange rate basis.

All profitability indicators also improved compared with the first nine months of 2006, particularly when the data are restated to eliminate the impact of extraordinary items, which had opposite effects in 2006 and 2007. EBIT and EBITDA totaled 34.7 million euros and 45.1 million euros, respectively, growing by 22.5% and 16.6%, respectively, when restated on a comparable basis.

Lastly, the Group reported a net income of 19.1 million euros, compared with 19 million euros at September 30, 2006.

Consistently with actual results, the Company estimates to close 2007 with almost 200 million euros in revenues, out of which 75% coming from international business.

* * *

Pursuant to Paragraph 2 of Article 154 *bis* of the Uniform Financial Code, Andrea Alberto Senaldi, the Company's Corporate Accounting Documents Officer, declares that the accounting information provided in this press release is consistent with the data in the supporting documents and in the Company's other documents and accounting records.

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group comprises 12 companies based in Europe, the United States, Central and South America and Asia. It has more than 800 employees, including 70 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, thyroid pathologies, oncology, fertility testing, etc.

Contacts

Investor Relations Officer

Laura Villa

DiaSorin S.p.A.

Hlaura.villa@diasorin.itH

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

Hbcaprioli@mailander.it

+39 335 590 14 02

INCOME STATEMENT

<i>(in thousands of euros)</i>	Third quarter		First nine months	
	2007 *	2006 *	2007 *	2006 *
Sales and service revenues	49,003	43,514	151,163	136,656
Cost of sales	(18,623)	(16,749)	(54,856)	(53,625)
Gross profit	30,380	26,765	96,307	83,031
	<i>62.0%</i>	<i>61.5%</i>	<i>63.7%</i>	<i>60.8%</i>
Sales and marketing expenses	(10,269)	(9,273)	(31,769)	(29,401)
Research and development costs	(2,736)	(2,164)	(8,144)	(6,691)
General and administrative expenses	(6,166)	(5,151)	(17,691)	(14,596)
	<i>-39.1%</i>	<i>-38.1%</i>	<i>-38.1%</i>	<i>-37.1%</i>
Other operating income (expenses)	(1,175)	1,819	(4,050)	1,127
<i>non-current portion</i>	<i>(1,855)</i>	<i>1,932</i>	<i>(4,508)</i>	<i>1,932</i>
EBIT	10,034	11,996	34,653	33,470
	<i>20.5%</i>	<i>27.6%</i>	<i>22.9%</i>	<i>24.5%</i>
Net financial income (expense)	(750)	(854)	(2,864)	(2,807)
Profit before taxes	9,284	11,142	31,789	30,663
Income taxes	(3,966)	(4,382)	(12,735)	(11,684)
Net profit	5,318	6,760	19,054	18,979
EBITDA ⁽¹⁾	13,452	15,480	45,093	44,014

* Unaudited data.

(1) The Company's defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of the EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

BALANCE SHEET*(in thousands of euros)***9/30/07****12/31/06****ASSETS**

Property, plant and equipment	34,370	35,502
Goodwill	48,055	48,055
Other intangibles	16,397	14,750
Equity investments	123	123
Deferred-tax assets	8,791	8,357
Other non-current assets	392	245

Total non-current assets **108,128** **107,032**

Inventories	34,027	30,891
Trade receivables	51,010	44,671
Accounts receivable from Group companies	21	-
Other current assets	4,292	2,769
Cash and cash equivalents	22,483	8,718

Total current assets **111,833** **87,049**

TOTAL ASSETS

219,961 **194,081**

LIABILITIES AND SHAREHOLDERS' EQUITY

Share capital	50,000	50,000
Reserves	8,636	7,486
Retained earnings (Loss carryforward)	29,819	7,957
Net profit for the period	19,054	22,294

Total shareholders' equity **112,509** **87,737**

Borrowings	29,406	33,556
Provisions for employee severance indemnities and other employee benefits	19,011	19,154
Deferred-tax liabilities	641	672
Other non-current liabilities	2,024	3,047

Total non-current liabilities **51,082** **56,429**

Trade payables	24,260	22,854
Accounts payable to Group companies	58	
Other current liabilities	14,123	12,508
Income taxes payable	8,968	4,633
Current portion of long-term debt	8,961	9,920

Total current liabilities **56,370** **49,915**

TOTAL LIABILITIES

107,452 **106,344**

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

219,961 **194,081**

CASH FLOW STATEMENT

<i>(in thousands of euros)</i>	Third quarter *		First nine months *	
	2007	2006	2007	2006
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	9,574	2,716	8,718	6,116
Net cash from operating activities	11,442	15,953	23,759	26,763
Cash used in investing activities	(3,150)	(3,420)	(11,207)	(12,233)
Cash used in financing activities	4,617	1,204	1,213	(4,193)
<i>Change in net cash and cash equivalents</i>	<i>12,909</i>	<i>13,737</i>	<i>13,765</i>	<i>10,337</i>
CASH AND CASH EQUIVALENTS AT END OF PERIOD	22,483	16,453	22,483	16,453

* Unaudited data.